OVER DEZE AFLEVERING
In the second edition of 'Quarterly catch-up', CMI Communications editors Emily McDonald and Erin McCreary round-up the biggest news in infectious diseases and review clinical microbiology and infectious diseases studies published in the second quarter of 2026 [1-4]. From Pneumocystis jirovecii pneumonia in solid-organ-transplant recipients to a double-blind randomised controlled trial reporting a new antibiotic for complicated urinary tract infections, Erin and Emily highlight four articles they found particularly noteworthy, and comment on whether the results can and should change clinical practice.
References
- Alanio A, et al. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a prospective observational cohort study, J Infect 2026. DOI: 10.1016/j.jinf.2026.106794
- Ramendra R, et al. Procalcitonin to guide 7 versus 14 days of antibiotics in bloodstream infections: a secondary analysis of the BALANCE trial, JAMA Netw Open 2026. DOI: 10.1001/jamanetworkopen.2026.20973
- Pai MP, et al. Challenging weight-tiered antibiotic prophylaxis in obese patients undergoing colorectal surgery using CT-derived body composition, CID 2026. DOI: 10.1093/cid/ciag383
- Takahashi S, et al. Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial. Lancet 2026. DOI: 10.1016/S0140-6736(26)00596-9
Further reading
- The SNAP Trial Group. Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia. NEJM 2026. DOI: 10.1056/NEJMoa2506905
- The SNAP Trial Group. Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial. Lancet 2026. DOI: 10.1016/S0140-6736(26)00761-0
- McCreary EK, et al. Communicable episode 26: SNAP out of it – rethinking anti-staphylococcal penicillins for S. aureus bacteremia, the SNAP trial PSSA/MSSA results. Communicable Podcast 2025. https://share.transistor.fm/s/2a3c3bb4
- Ilges D, et al. Anticalcitonin: limited utility of a context-dependent biomarker demonstrated in another real-world data set, CID 2026. DOI: https://doi.org/10.1093/cid/ciag396
- Spellberg B. Procalcitonin–An enigmatic anxiolytic biomarker, JAMA Netw Open 2026. DOI: 10.1001/jamanetworkopen.2026.20978
Engels
Verenigde Staten
IN DEZE AFLEVERING
TRANSCRIPTIE 🔗
Communicable E60: Quarterly catch-up, August 2026
===
Angela: [00:00:00] Hello, Communicable listeners. I'm Angela Huttner, editor-in-chief of CMI Communications and clinical trial enthusiast. I've got a couple fellow enthusiasts with me Josh Davis and Steve Tong to tell you about a post-graduate education course we've planned for this November in Malta.
Josh: This is a two and a half days, so Thursday, Friday and half day Saturday, The content is aimed at anyone who wants to do clinical trial…
===
Angela: [00:00:00] Hello, Communicable listeners. I'm Angela Huttner, editor-in-chief of CMI Communications and clinical trial enthusiast. I've got a couple fellow enthusiasts with me Josh Davis and Steve Tong to tell you about a post-graduate education course we've planned for this November in Malta.
Josh: This is a two and a half days, so Thursday, Friday and half day Saturday, The content is aimed at anyone who wants to do clinical trial…
OUDE AFLEVERINGEN ZOEKEN
Zoek naar eerdere afleveringen van Communicable.
Disclaimer: De podcast en de illustraties die op deze pagina zijn ingesloten, zijn afkomstig van CMI Communications, eigendom van de eigenaar en niet gelieerd aan of goedgekeurd door Listen Notes, Inc.
BEWERKEN
Bedankt voor uw hulp bij het up-to-date te houden van de podcast-database .